<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304237</url>
  </required_header>
  <id_info>
    <org_study_id>VICTORIA</org_study_id>
    <nct_id>NCT02304237</nct_id>
  </id_info>
  <brief_title>Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Investigator Initiated Trial of Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Han Wha Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ewha Womans University Mokdong Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for compare the efficacy of two different regimens(vaginal vs intramuscular) of
      progesterone therapy in prevention of preterm birth in high risk pregnant women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study is 1) To compare the efficacy of two different regimens of
      progesterone therapy in preventing preterm birth less than 37 weeks of gestation. 2) To
      compare the cost-benefit, adverse effects and patient preference of two different regimens of
      progesterone therapy.

      Design: Multi-center, randomized, open-label trial
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm Birth Rate before 37 weeks of gestation</measure>
    <time_frame>from study enrollment to maximum 37 weeks of gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth Rate before 34 weeks of gestation</measure>
    <time_frame>from study enrollment to maximum 34 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth Rate before 28 weeks of gestation</measure>
    <time_frame>from study enrollment to maximum 28 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Result of birth(rate of death, weight, cause of hospitalization to NICU)</measure>
    <time_frame>from study enrollment to maximum 37 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any complications occurred to newborn and mother</measure>
    <time_frame>from study enrollment to maximum 37 weeks of gestation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Vaginal progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaginal progesterone(Utrogestan)200mg/day, during 14~21 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular progesterone(Progesterone Depot Jenapharm Injection)250mg/week, during 14~21 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal progesterone</intervention_name>
    <description>micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes</description>
    <arm_group_label>Vaginal progesterone</arm_group_label>
    <other_name>Utrogestan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular progesterone</intervention_name>
    <description>hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes</description>
    <arm_group_label>Intramuscular progesterone</arm_group_label>
    <other_name>Progesterone Depot Jenapharm Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With a history of prior spontaneous preterm birth or short cervix length

          -  Spontaneous preterm birth: preterm birth &lt;37 weeks of gestation due to spontaneous
             preterm labor or preterm premature rupture of membranes (PPROM)

          -  Short Cervix length : cervix length &lt;25 mm as measured by transvaginal ultrasound at
             16-24 weeks of gestation

        Exclusion Criteria:

          -  Multiple gestations

          -  Major congenital anomalies

          -  Elective prophylactic cervical cerclage &lt;16 weeks of gestation during current
             pregnancy

          -  Previous intentional preterm birth due to maternal or fetal indications, such as
             preeclampsia and fetal growth restriction

          -  Diabetes, hypertension, other severe medical diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Ju Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Ju Kim</last_name>
    <phone>822-2650-5500</phone>
    <email>kkyj@ewha.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SUK-JOO CHOI</last_name>
    <phone>822-3410-3546</phone>
    <email>drmaxmix.choi@samsung.com</email>
  </overall_contact_backup>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University Mokdong Hospital</investigator_affiliation>
    <investigator_full_name>Young Ju Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Premature Birth</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

